Tag: hepatocellular carcinoma (HCC)

1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events ...

1. Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events ...

1. Progression-free survival was significantly greater in the lenvatinib plus pembrolizumab group compared to placebo. 2. Overall survival was higher ...

1. In this cohort study involving noncirrhotic patients with chronic hepatitis B, a new prognostic model based on viral load ...

1. Patients in the camrelizumab-rivoceranib group reported significantly greater progression-free survival than the sorafenib group. 2. Treatment-related deaths were comparable ...

This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...

This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...

1. Patients with NAFLD-related HCC have longer disease-free survival compared to those with HCC from other causes. 2. Tumours of ...

1. The median overall survival for nivolumab was 16.4 months and for sorafenib was 14.7 months 2. Patients receiving nivolumab ...

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally ...